Premier rewards Inova for innovation

Inova, a five-hospital healthcare system in the Washington, D.C., metro area has been nationally recognized with the 2016 Premier Excellence Award.

Premier, a healthcare improvement company, selected Inova “for exemplifying the highest level of industry innovation and advancement in delivering high-quality, cost-effective care across Premier’s alliance of approximately 3,600 U.S. hospitals and 120,000 other providers,” according to a release.

“Inova’s consistent drive to accelerate healthcare innovation and excellence, coupled with their willingness to share best practices, is setting an industry standard,” said Susan DeVore, Premier’s president and CEO. “We’re proud to recognize their many accomplishments, as they are an integral part of the Premier alliance.”

Through its collaboration with Premier over the past two and a half years, Inova has reduced mortality and readmissions, achieved unprecedented “A” grades in national patient safety ratings at all five hospitals, and saved more than $250 million in total care costs. More than $50 million in savings is attributed to supply chain costs alone.

“This award is the result of true collaboration,” said Inova President and COO Mark Stauder. “The Premier alliance is a strong and powerful network of providers working together to move from reactive to preventive to predictive medicine so we can fundamentally transform healthcare.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.